BTG Limited provides various therapeutic solutions for a range of complex medical problems in the United States, Europe, and internationally. Its interventional oncology products include TheraSphere, and embolization and chemoembolization polymer beads that are used in the treatment of primary liver cancer, as well as when tumours from other organs spread to the liver; and cryoablation systems and needles. The company’s vascular products comprise EKOS blood clot treatment devices, arterial blockage crossing devices, and Sentry inferior vena cava filters, as well as Varithena, a varicose vein treatment product. It also offers PneumRx, a coils emphysema technology; and acute care products that provide rescue medication to patients. The company was incorporated in 1991 and is based in London, the United Kingdom. BTG Limited operates as a subsidiary of Bravo Bidco Limited.
Metrics to compare | BTG | Peers Peers - average of corresponding metrics from companies closely matching BTG: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBTGPeersSector |
---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | 0.0x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 0.0x | |
Price / LTM Sales | 0.0x | 0.0x | 0.0x | |
Upside (Analyst Target) | 0.0% | 0.0% | 0.0% | |
Fair Value Upside | Unlock | 0.0% | 0.0% | Unlock |